RECKITT BENCKIS/S (RBGLY) Rating Increased to Hold at Zacks Investment Research

RECKITT BENCKIS/S (OTCMKTS:RBGLY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.

According to Zacks, “Reckitt Benckiser Group Plc engages in manufacturing and distributing household, toiletry, pharmaceutical and food products. The company offers antiseptic liquids, depilatory products, medicated sore throat products, condoms, cold/flu products, acne treatment products, analgesics and upper gastro-intestinal products, foot care and comfort footwear products, denture care and dry skin care products, fabric care products, surface care products and polishes/waxes. Reckitt Benckiser Group is based in Slough, the United Kingdom. “

Separately, Jefferies Financial Group cut RECKITT BENCKIS/S from a “hold” rating to an “underperform” rating in a report on Thursday, January 24th.

OTCMKTS:RBGLY opened at $16.04 on Thursday. RECKITT BENCKIS/S has a fifty-two week low of $14.64 and a fifty-two week high of $18.67. The company has a current ratio of 0.65, a quick ratio of 0.48 and a debt-to-equity ratio of 0.65. The stock has a market cap of $56.38 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 9.28 and a beta of 0.87.

About RECKITT BENCKIS/S

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

See Also: Penny Stocks

Get a free copy of the Zacks research report on RECKITT BENCKIS/S (RBGLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.